Corentec Co

Corentec Co LT Debt/Equity

The Long-Term Debt to Equity Ratio of Corentec Co (104540.KQ) as of Nov 6, 2026 is 0.06. In the previous year, Long-Term Debt to Equity Ratio was 0.07 — a change of -17.26% (lower).

LT Debt/Equity

0.06

YoY

-17.26%

Last updated:

Long-Term Debt to Equity Ratio of Corentec Co is 2025 0.06 . Long-Term Debt to Equity Ratio of Corentec Co was 2024 0.07 . It decreases by -17.26% lower compared to the previous year.

The Corentec Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
0.99 KRW
Jan 1, 2019
0.07 KRW
Jan 1, 2020
0.34 KRW
Jan 1, 2021
0.51 KRW
Jan 1, 2022
0.29 KRW
Jan 1, 2023
0.02 KRW
Jan 1, 2024
0.07 KRW
Jan 1, 2025
0.06 KRW
The Corentec Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.06-17.26%
0.07+222.78%
0.02-92.56%
0.29-43.20%
0.51+51.40%
0.34+372.35%
0.07-92.81%
0.99+127.64%
0.44+49.55%
0.29+8,648.69%
0.00-97.11%
0.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Corentec Co Stock analysis

What does Corentec Co do? Corentec Co., Ltd. manufactures and sells artificial articulations, including hip, knee, and spine products. The company offers hip products under the BENCOX brand, featuring primary systems, hemi-arthroplasty systems, and revision systems such as cementless femoral stems and acetabular cups. Knee products are sold under the LOSPA brand, including fixed and mobile primary knee systems and revision systems. Spine products also carry the LOSPA IS brand, comprising pedicle screws and peek cages. Corentec distributes these products domestically and internationally, targeting healthcare providers and hospitals that require orthopedic solutions. The firm’s revenue comes from the sale of hip, knee, and spine products through its BENCOX, LOSPA, and LOSPA IS brand portfolios. Domestic and overseas markets are key segments, with the company focusing on orthopedic surgeons and medical institutions that purchase these specialized medical devices. Corentec’s product lines are designed for both primary and revision surgeries, catering to a broad range of orthopedic needs in the healthcare sector. Corentec Co., Ltd. serves healthcare providers globally, with its BENCOX brand dominating hip product sales and LOSPA/LOSPA IS covering knee and spine solutions. The company’s distribution strategy emphasizes direct sales to hospitals and medical centers, ensuring consistent product availability for surgical procedures. By maintaining distinct brand identities for each product category, Corentec efficiently targets specific medical specialties within the orthopedic market. Corentec Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Corentec Co stock

Long-Term Debt to Equity Ratio of Corentec Co is 0.06 in 2025.

Long-Term Debt to Equity Ratio of Corentec Co changed from 0.07 to 0.06, representing a -17.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Corentec Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Corentec Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Corentec Co

All Key Metrics — Corentec Co